AR046205A1 - PHARMACEUTICAL FORMULATION OF LICOFELONA - Google Patents

PHARMACEUTICAL FORMULATION OF LICOFELONA

Info

Publication number
AR046205A1
AR046205A1 ARP040103905A ARP040103905A AR046205A1 AR 046205 A1 AR046205 A1 AR 046205A1 AR P040103905 A ARP040103905 A AR P040103905A AR P040103905 A ARP040103905 A AR P040103905A AR 046205 A1 AR046205 A1 AR 046205A1
Authority
AR
Argentina
Prior art keywords
water soluble
pharmaceutical formulation
copolymers
soluble polymer
licofelona
Prior art date
Application number
ARP040103905A
Other languages
Spanish (es)
Inventor
F Sievert
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Publication of AR046205A1 publication Critical patent/AR046205A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulación farmacéutica sólida que comprende licofelona o una sal farmacéuticamente aceptable de la misma y por lo menos un polímero soluble en agua seleccionado entre hidroxialquil celulosa, metil celulosa, polivinil pirrolidonas y copolímeros de los mismos, alcoholes polivinílicos, copolímeros hidrolizados o parcialmente hidrolizados de N-vinilpirrolidona y ésteres vinílicos, y/o por lo menos un poliol soluble en agua seleccionado entre polietilen glicoles con un peso molecular que oscila entre 8000 y 20000 y alcoholes de azúcares. La formulación libera con rapidez el ingrediente activo. Uso de un polímero soluble en agua y/o un poliol soluble en agua para producir dicha formulación farmacéutica.Solid pharmaceutical formulation comprising licofelone or a pharmaceutically acceptable salt thereof and at least one water soluble polymer selected from hydroxyalkyl cellulose, methyl cellulose, polyvinyl pyrrolidones and copolymers thereof, polyvinyl alcohols, hydrolyzed or partially hydrolyzed N- copolymers vinyl pyrrolidone and vinyl esters, and / or at least one water soluble polyol selected from polyethylene glycols with a molecular weight ranging from 8,000 to 20,000 and sugar alcohols. The formulation quickly releases the active ingredient. Use of a water soluble polymer and / or a water soluble polyol to produce said pharmaceutical formulation.

ARP040103905A 2003-10-31 2004-10-27 PHARMACEUTICAL FORMULATION OF LICOFELONA AR046205A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10351035A DE10351035A1 (en) 2003-10-31 2003-10-31 Pharmaceutical Licofelone formulation

Publications (1)

Publication Number Publication Date
AR046205A1 true AR046205A1 (en) 2005-11-30

Family

ID=34485181

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103905A AR046205A1 (en) 2003-10-31 2004-10-27 PHARMACEUTICAL FORMULATION OF LICOFELONA

Country Status (4)

Country Link
AR (1) AR046205A1 (en)
DE (1) DE10351035A1 (en)
TW (1) TW200524592A (en)
WO (1) WO2005041920A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109718220A (en) * 2017-10-27 2019-05-07 天津药物研究院有限公司 The preparation method of ML-4000 clathrate capsule
EP3593792A1 (en) 2018-07-11 2020-01-15 Welding GmbH & Co. KG Pharmaceutical composition comprising 6- (4-chlorophenyl) -2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid cholin salt
WO2023089636A1 (en) * 2021-11-21 2023-05-25 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of licofelone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
JP2000504723A (en) * 1996-02-13 2000-04-18 ジー．ディー．サール アンド カンパニー Immunosuppressive effect of administration of cyclooxygenase-2 inhibitor and 5-lipoxygenase inhibitor
DE10121252A1 (en) * 2001-04-30 2002-11-07 Christos C Zouboulis Acne treatment
JP2006509720A (en) * 2002-05-17 2006-03-23 メルクル・ゲーエムベーハー Cycloaddition pyrrole compounds as proton pump inhibitors for ulcer treatment

Also Published As

Publication number Publication date
WO2005041920A3 (en) 2005-07-14
DE10351035A1 (en) 2005-05-25
TW200524592A (en) 2005-08-01
WO2005041920A2 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
CO5261563A1 (en) PHARMACEUTICAL COMPOSITIONS THAT PROVIDE POWERFUL FARMACO CONCENTRATIONS
NL301005I2 (en) Aliskiren or a pharmaceutically acceptable salt thereof; and hydrochlorothiazide or a pharmaceutically acceptable salt thereof
DK1183014T3 (en) Flavored controlled release oral pharmaceutical compositions
ITMI20001173A0 (en) EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS FOR THE PARENTERAL ADMINISTRATION OF BIOLOGICALLY ACTIVE HYDROPHILIC SUBSTANCES.
PE20061160A1 (en) DRUG ADMINISTRATION SYSTEM WITH GASTRIC RETENTION
NO20011471D0 (en) New oral sustained release formulations
PE20040131A1 (en) FORMULATIONS AND DOSAGE FORMS FOR CONTROLLED ADMINISTRATION OF TOPIRAMATE
CY1116023T1 (en) FORMS OF PHARMACEUTICAL DOSAGE CONTROLLED DETERMINATION WITH PHARMACEUTICAL DISSOLUTION LIMITATIONS
RS50303B (en) Controlled release pharmaceutical composition comprising nimesulide
ECSP045102A (en) Pharmaceutical formulation containing 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and provides a delayed release of the active ingredient
AR044131A1 (en) ORALLY FAST DISSOLVING CONSUMABLE FILMS CONTAINING A MODIFIED ALMIDON FOR THE IMPROVEMENT OF HEAT AND HUMIDITY RESISTANCE
PE20061449A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING IMATINIB AND A RELEASE RETARDER
AR069552A1 (en) FORMULATIONS FOR THE TREATMENT OF SEEDS AND METHODS OF USE
ES2194732T3 (en) ORAL PHARMACEUTICAL COMPOSITIONS OF CONTROLLED LIBERATION OF MESALAZINE.
AR077411A2 (en) SOLID PHARMACEUTICAL DOSAGE FORM, WITH LOPINAVIR AND RITONAVIR, AND PROCESS FOR PREPARATION.
ATE372765T1 (en) SOLID PHARMACEUTICAL FORMULATIONS CONTAINING TELMISARTAN
NO20024919L (en) Hydrophilic / lipophilic polymer matrix dosage formulation
BR0107869A (en) Electrogenated pharmaceutical compositions
AR013117A1 (en) A SOLID PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET THAT INCLUDES A BENZOFURAN DERIVATIVE WITH ANTIARRHYTHMIC ACTIVITY ADAPTED FOR ORAL ADMINISTRATION
NO974194D0 (en) Improvements in, or related to, organic compositions
AR026968A1 (en) A MATRIX TABLET THAT ALLOWS THE PROLONGED TRIMETAZIDINE RELEASE AFTER YOUR ADMINISTRATION BY ORAL ROUTE
ES2111547T3 (en) PROLONGED RELEASE TABLET.
AR018862A1 (en) PHARMACEUTICAL FORMULATION OF PROLONGED RELEASE, IMPROVED FOR THE ORAL ADMINISTRATION OF NEFAZODONA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME; ORAL DOSAGE FORM THAT UNDERSTANDS AND USE OF SUCH FORMULATION TO PREPARE THE SUCH DOSAGE FORM
BR9814756A (en) Dry solid composition for drug release, process for drug preparation, use of a large number of small spheres that contain a polymeric matrix composed of a polyethylene glycol or a mixture of polyethylene glycols
ITMI20022292A1 (en) 9A-AZALIDS WITH ANTI-INFLAMMATORY ACTIVITY.

Legal Events

Date Code Title Description
FB Suspension of granting procedure